Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

Authors:
  • LGLinda A. Gallo
    Linda A. Gallo
  • MWMicheal S. Ward
    Micheal S. Ward
  • AFAmelia K. Fotheringham
    Amelia K. Fotheringham
  • DBDanielle J. Borg
    Danielle J. Borg
  • NFNicole B. Flemming
    Nicole B. Flemming
  • BHBen M. Harvie
    Ben M. Harvie
  • TKToni L. Kinneally
    Toni L. Kinneally
  • SYShang-Ming Yeh
    Shang-Ming Yeh
  • DMDomenica A. McCarthy
    Domenica A. McCarthy
  • HKHermann Koepsell
    Hermann Koepsell
  • VVVolker Vallon
    Volker Vallon

Abstract
Scientific Reports 6: Article number: 26428; published online: 26 May 2016; updated: 07 July 2016 This Article contains errors in the Acknowledgements section. “The authors acknowledge funding support from the National Health and Medical Council of Australia (1004926).” should read: “The authors acknowledge funding support from the National Health and Medical Research Council of Australia (1004926) and Diabetes Australia.